European Sales Down For Novartis In Q210

BMI believes Novartis's Q210 results reinforce our view that emerging markets will drive industry growth. The company delivered a strong performance in H110, posting an 18% increase in net sales to US$23.8bn. However, on comparing Novartis's financial performance between Q2 and Q1, it is evident that the company has suffered at the hands of cost-containment measures implemented by governments in developed states - particularly by governments across Europe - over the past six months.

To read the full article, please choose one of the following options: